14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:FMTX
Delisted

Forma Therapeutics Holdings Inc. Stock Price (Quote)

NASDAQ Stock Exchange > Healthcare > Biotechnology
Open Broker Account
$20.01
+0 (+0%)
At Close: Jan 27, 2023
Forecast Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $20.01 $20.01 Friday, 27th Jan 2023 FMTX stock ended at $20.01. During the day the stock fluctuated 0% from a day low at $20.01 to a day high of $20.01.
90 days $20.01 $20.01
52 weeks $4.95 $20.28

Historical Forma Therapeutics Holdings Inc. prices

Date Open High Low Close Volume
Jan 27, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 26, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 25, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 24, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 23, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 20, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 19, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 18, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 17, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 13, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 12, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 11, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 10, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 09, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 06, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 05, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 04, 2023 $20.01 $20.01 $20.01 $20.01 0
Jan 03, 2023 $20.01 $20.01 $20.01 $20.01 0
Dec 30, 2022 $20.01 $20.01 $20.01 $20.01 0
Dec 29, 2022 $20.01 $20.01 $20.01 $20.01 0
Dec 28, 2022 $20.01 $20.01 $20.01 $20.01 0
Dec 27, 2022 $20.01 $20.01 $20.01 $20.01 0
Dec 23, 2022 $20.01 $20.01 $20.01 $20.01 0
Dec 22, 2022 $20.01 $20.01 $20.01 $20.01 0
Dec 21, 2022 $20.01 $20.01 $20.01 $20.01 0
Click to get the best stock tips daily for free!

About Forma Therapeutics Holdings Inc.

Forma Therapeutics Holdings. Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company... FMTX Profile

Golden Star

Ticker Date Change Price
BSCQ Apr 30 0.393% $19.09
EQC Apr 30 1.76% $18.72
HRB Apr 30 1.69% $47.23
REG Apr 30 1.35% $59.22
INGR Apr 30 0.576% $114.59
BSJP Apr 29 0.175% $22.91
LYG Apr 29 0.781% $2.56
ORA Apr 29 3.46% $64.48
DHT Apr 24 4.34% $11.28
LPLA Apr 19 2.62% $262.59
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT